Study of Metastatic Ocular Melanoma

Charité University Medicine Berlin

Status and phase: Unknown; Phase 2

Conditions: Ocular Melanoma

Treatments: Drug: Treosulfan; Drug: Gemcitabine

Study type: Interventional

Funder types: Other

Identifiers

NCT00168870

Haema CBF AHM UK/AS 04

Details and patient eligibility

About

This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma.

Full description

Treatment of patients with metastatic ocular melanoma with combination chemotherapy Gemcitabine and Treosulfan versus monotherapy with Treosulfan as first-line chemotherapy.

Enrollment: 48 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Metastatic ocular melanoma

Exclusion criteria

• Prior treatment with chemotherapy
• Active 2nd malignancy
• Cerebral metastasis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)